Physician profile
Ankush Sharma
NPI 1649433616
$7,307.05
in general payments reported to CMS, 2019-2025
32 companies · $2,119 in 2025
The $2,119 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $516 · 2020: $283 · 2021: $559 · 2022: $806 · 2023: $1,166 · 2024: $1,858 · 2025: $2,119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,081 · Education: $62.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,080.73 |
| Education | $62.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,955.41 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $519.97 | 2022-2025 | Stelara, Simponi Aria, Simponi |
| Celgene Corporation | $405.26 | 2022-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $363.40 | 2019-2024 | Entyvio, Gattex |
| Pfizer INC. | $298.52 | 2020-2025 | |
| Madrigal Pharmaceuticals | $209.63 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $197.58 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $183.56 | 2019-2023 | Trulance |
| Novo Nordisk INC | $144.02 | 2023-2025 | Wegovy |
| Galderma Laboratories, L.P. | $135.24 | 2025 | Nemluvio |
| Qol Medical, LLC | $120.35 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $103.47 | 2022 | |
| Ardelyx, INC. | $83.08 | 2022-2024 | Ibsrela |
| Ferring Pharmaceuticals INC. | $78.85 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $72.42 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $58.90 | 2023-2024 | Andexxa |
| Ironwood Pharmaceuticals, INC | $55.62 | 2020-2023 | Linzess |
| Redhill Biopharma INC. | $47.27 | 2021-2024 | Talicia |
| Intercept Pharmaceuticals, INC. | $42.64 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $32.65 | 2025 | Iqirvo |
| Shionogi INC | $21.09 | 2019 | |
| Celltrion USA INC. | $21.04 | 2024 | Vegzelma |
| Evoke Pharma, INC. | $20.99 | 2022 | |
| Aimmune Therapeutics, INC. | $19.93 | 2025 | Vowst |
| Genentech, INC. | $18.68 | 2019 | |
| Allergan, INC. | $17.61 | 2019 | |
| Fujifilm Healthcare Americas Corporation | $15.73 | 2024 | Utaswako Afp-L3 |
| Braintree Laboratories, INC. | $15.37 | 2024 | Sutab, Suflave |
| Vivus LLC | $14.82 | 2025 | Pancreaze |
| Apollo Endosurgery US INC | $13.71 | 2022 | |
| Phadia US INC. | $11.82 | 2022 | |
| Endogastric Solutions, INC | $8.42 | 2023 | Esophyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ankush Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.